keyword
MENU ▼
Read by QxMD icon Read
search

breast neoadjuvant chemotherapy

keyword
https://www.readbyqxmd.com/read/28324267/chemotherapy-induced-irreversible-alopecia-in-early-breast-cancer-patients
#1
Gun Min Kim, Sanghwa Kim, Hyung Seok Park, Jee Ye Kim, Sanggen Nam, Seho Park, Seung Il Kim, DoYoung Kim, Joohyuk Sohn
PURPOSE: The purpose of this work is to determine the prevalence of chemotherapy-induced irreversible alopecia (CIIA), which is defined as an alopecia that exists at least 6 months after completion of chemotherapy and factors affecting CIIA in early breast cancer patients. METHODS: We performed a cross-sectional study. We retrospectively identified breast cancer patients who had received AC (Adriamycin, Cyclophosphamide) or AC-T (AC followed by Taxane) as neoadjuvant or adjuvant chemotherapy...
March 21, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28315068/efficacy-and-safety-of-nab-paclitaxel-125%C3%A2-mg-m-2-and-nab-paclitaxel-150%C3%A2-mg-m-2-compared-to-paclitaxel-in-early-high-risk-breast-cancer-results-from-the-neoadjuvant-randomized-geparsepto-study-gbg-69
#2
Jenny Furlanetto, Christian Jackisch, Michael Untch, Andreas Schneeweiss, Sabine Schmatloch, Bahriye Aktas, Carsten Denkert, Hermann Wiebringhaus, Sherko Kümmel, Mathias Warm, Stefan Paepke, Marianne Just, Claus Hanusch, John Hackmann, Jens Uwe Blohmer, Michael Clemens, Serban Dan Costa, Bernd Gerber, Valentina Nekljudova, Sibylle Loibl, Gunter von Minckwitz
PURPOSE: The GeparSepto study demonstrated that the use of nab-paclitaxel instead of paclitaxel prior to anthracycline-based chemotherapy could lead to a significantly increased pCR rate, especially in the triple negative subpopulation. We report efficacy and safety for patients treated with two different doses of nab-paclitaxel in comparison to weekly solvent-formulated paclitaxel. METHODS: Patients were treated for 12 weeks with either intravenous nab-paclitaxel 150 mg/m(2) (nP150) weekly, after study amendment 125 mg/m(2) (nP125) weekly or solvent-based paclitaxel 80 mg/m(2) (P80) weekly followed by epirubicin 90 mg/m(2) and cyclophosphamide 600 mg/m(2) on day 1 for four 3-week cycles...
March 17, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28314842/performance-of-mid-treatment-breast-ultrasound-and-axillary-ultrasound-in-predicting-response-to-neoadjuvant-chemotherapy-by-breast-cancer-subtype
#3
Rosalind P Candelaria, Roland L Bassett, William Fraser Symmans, Maheshwari Ramineni, Stacy L Moulder, Henry M Kuerer, Alastair M Thompson, Wei Tse Yang
BACKGROUND: The primary objective was to determine whether mid-treatment ultrasound measurements of index breast tumors and index axillary nodes of different cancer subtypes associate with residual cancer burden (RCB). METHODS: Patients with invasive breast cancer who underwent neoadjuvant chemotherapy and had pre-treatment and mid-treatment breast and axillary ultrasound were included in this single-institution, retrospective cohort study. Linear regression analysis assessed associations between RCB with (a) change in index breast tumor size, (b) change in index node size, and (c) absolute number of abnormal nodes at mid-treatment...
March 17, 2017: Oncologist
https://www.readbyqxmd.com/read/28295828/are-the-acosog-z0011-trial-findings-being-applied-to-breast-cancer-patients-undergoing-neoadjuvant-chemotherapy
#4
Olga Kantor, Catherine Pesce, Erik Liederbach, Chi-Hsiung Wang, David J Winchester, Katharine Yao
In 2010, the ACOSOG Z0011 trial showed equivalent survival and recurrence between sentinel lymph node biopsy (SLNB) alone versus axillary lymph node dissection (ALND) for those with a tumor positive sentinel node (SN). We examined national trends in axillary surgery following neoadjuvant chemotherapy (NAC) for clinically node positive disease in the years prior to and after the Z0011 trial publication. 12,063 women with cT1-4N1M0 invasive breast cancer who underwent NAC from 2006 to 2013 and had 1-3 positive nodes on pathology were selected from the National Cancer Data Base...
March 13, 2017: Breast Journal
https://www.readbyqxmd.com/read/28289852/tumor-infiltrating-lymphocytes-and-molecular-response-after-neoadjuvant-therapy-for-hr-her2-%C3%A2-breast-cancer-results-from-two-prospective-trials
#5
M V Dieci, A Frassoldati, D Generali, G Bisagni, F Piacentini, L Cavanna, K Cagossi, F Puglisi, A Michelotti, R Berardi, G Banna, A Goubar, G Ficarra, G Griguolo, Pierfranco Conte, V Guarneri
PURPOSE: The aim was to evaluate the role of tumor-infiltrating lymphocytes (TIL) in predicting molecular response after preoperative endocrine or cytotoxic treatment for HR+/HER2- patients who do not achieve a pathological complete response. METHODS: Stromal (Str) TIL were centrally evaluated on samples from diagnostic core-biopsies of HR+/HER2- patients included in two prospective randomized trials: the LETLOB trial (neoadjuvant endocrine-based treatment) and the GIOB trial (neoadjuvant chemotherapy-based treatment)...
March 13, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28284519/breast-conserving-surgery-and-locoregional-control-after-neoadjuvant-chemotherapy
#6
REVIEW
M Teshome, H M Kuerer
The management of breast malignancy and the role of neoadjuvant systemic therapy has continued to evolve over the past 50 years. Survival equivalence with adjuvant systemic therapy is well accepted and demonstrated in several clinical trials. However, strong association with survival outcome and pathologic complete response emerged. Assessment of tumor response, as a surrogate for outcome, continues to be a driver for neoadjuvant therapy with increased applicability in the setting of sophisticated understanding and implications of breast tumor biology and molecular subtype...
February 12, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28282999/critical-decision-making-in-radiotherapy-for-early-stage-breast-cancer-in-a-neo-adjuvant-treatment-era
#7
Francesca De Felice, Mattia Falchetto Osti, Vitaliana De Sanctis, Daniela Musio, Vincenzo Tombolini
Introduction In breast cancer management, the role of adjuvant radiation therapy (RT) has been the subject of intense controversy over the past several years, due to the improvement in neoadjuvant chemotherapy (NACT) prescription. One of the most controversial questions regarding indication for adjuvant RT is whether or not RT is essential in patients with early stage disease at diagnosis. The value of adjuvant RT remains highly debatable in those patients with clinically negative nodes at the completion of NACT...
March 10, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28279941/long-term-outcome-of-the-remagus-02-trial-a-multicenter-randomised-phase-ii-trial-in-locally-advanced-breast-cancer%C3%A2-patients-treated-with-neoadjuvant-chemotherapy-with-or-without-celecoxib-or-trastuzumab-according-to-her2-status
#8
Sylvie Giacchetti, Anne-Sophie Hamy, Suzette Delaloge, Etienne Brain, Frédérique Berger, Brigitte Sigal-Zafrani, Marie-Christine Mathieu, Philippe Bertheau, Jean Marc Guinebretière, Mahasti Saghatchian, Florence Lerebours, Chafouny Mazouni, Olivier Tembo, Marc Espié, Fabien Reyal, Michel Marty, Bernard Asselain, Jean-Yves Pierga
BACKGROUND: The REMAGUS-02 multicenter randomised phase II trial showed that the addition to neoadjuvant chemotherapy (NAC) of trastuzumab in patients with localised HER2-positive breast cancer (BC) increased the pathological complete response (pCR) rate and that the addition of celecoxib in HER2-negative cases did not increase the pCR rate. We report here the long-term follow-up results for disease-free survival (DFS) and overall survival (OS). PATIENTS AND METHODS: From 2004 to 2007, 340 stage II-III BC patients were randomly assigned to receive neoadjuvant EC-T (four cycles of epirubicin-cyclophosphamide followed by four cycles of docetaxel) +/- celecoxib in HER2-negative cases (n = 220) and ± trastuzumab in HER2-positive cases (n = 120)...
March 6, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28277293/prospective-comparison-of-outcome-after-treatment-for-triple-negative-and-non-triple-negative-breast-cancer
#9
D P Joyce, D Murphy, A J Lowery, C Curran, K Barry, C Malone, R McLaughlin, M J Kerin
INTRODUCTION: Triple-negative breast cancers (TNBC) are associated with a poor prognosis owing to an aggressive phenotype. We aimed to carry out a prospective study comparing management strategies and response to therapy in TNBC and non-TNBC patients. METHODS: Data were obtained from a prospectively maintained database of patients treated for breast cancer. RESULTS: A total of 142 TNBC and 142 age-, stage- and NPI-matched non-TNBC patients were treated...
October 27, 2016: Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
https://www.readbyqxmd.com/read/28276033/effect-of-neoadjuvant-chemotherapy-on-her-2-expression-in-surgically-treated-gastric-and-oesophagogastric-junction-carcinoma-a-multicentre-italian-study
#10
Damiano Chiari, Elena Orsenigo, Giovanni Guarneri, Gian Luca Baiocchi, Elena Mazza, Luca Albarello, Massimiliano Bissolati, Sarah Molfino, Carlo Staudacher
Predictors of response to neoadjuvant chemotherapy are not available for gastric and oesophago-gastric junction carcinoma. HER-2 over-expression in breast cancer correlates with poor prognosis and high incidence of recurrence. First aim of this study was to evaluate if the HER-2 expression/amplification is predictive of response to neoadjuvant chemotherapy in terms of pathologic regression. Secondary aim was to evaluate if HER-2 expression varies after neoadjuvant treatment. Thirty-five patients with locally advanced gastric or oesophago-gastric junction carcinoma underwent preoperative chemotherapy and surgical resection at San Raffaele Scientific Institute and Spedali Civili of Brescia...
March 8, 2017: Updates in Surgery
https://www.readbyqxmd.com/read/28275922/scalp-cooling-with-adjuvant-neoadjuvant-chemotherapy-for-breast-cancer-and-the-risk-of-scalp-metastases-systematic-review-and-meta-analysis
#11
REVIEW
Hope S Rugo, Susan A Melin, Jeff Voigt
PURPOSE: The risk of scalp metastases in patients using scalp cooling for preservation of hair during chemotherapy has been a concern but is poorly described. METHODS: A systematic review and meta-analysis of longitudinal studies was undertaken to evaluate the effect of scalp cooling versus no scalp cooling on the risk of scalp metastasis in patients treated for breast cancer with chemotherapy. Electronic databases, journal specific, and hand searches of articles identified were searched...
March 8, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28272714/role-of-dwi-assessing-nodal-involvement-and-response-to-neoadjuvant-chemotherapy-in-advanced-breast-cancer
#12
P Belli, E Bufi, C Buccheri, P Rinaldi, M Giuliani, M Romani, G Fabrizi, A D'angelo, C Brunelli, A Mule', G Franceschini, C Colosimo
OBJECTIVE: To explore the role of diffusion-weighted imaging (DWI) in the staging of axillary lymph nodes and the restaging after neoadjuvant chemotherapy (NAD) in advanced breast cancer. PATIENTS AND METHODS: MRI examinations of forty-two patients diagnosed with advanced breast cancer addressed to NAD and axillary lymph node dissection (ALND) were reviewed. Apparent diffusion coefficients (ADC) of each visible node in DWI in the pathologic axilla (PA) and healthy axilla (HA) were measured at the time of diagnosis (t0) and after chemotherapy (t1); mean values of the ADC were calculated...
February 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28271747/short-term-outcomes-of-neoadjuvant-hormonal-therapy-versus-neoadjuvant-chemotherapy-in-breast-cancer-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#13
Lei Huang, A-Man Xu
Estrogen receptor positive (ER(+)) breast cancer (BC) is highly hormonal therapy-responsive. The choice between neoadjuvant hormonal therapy (NHT) and neoadjuvant chemotherapy (NCT) remains controversial. The aim of this meta-analysis was to evaluate benefits and safety of NHT compared with NCT for operable BC patients. Areas covered: Electronic databases were searched to identify randomized clinical trials (RCTs) comparing NHT and NCT for treatment of invasive and immunohistochemically ER(+) BC. Major outcomes were clinical response rate, pathologic complete response (pCR), operation methods, recurrence, and adverse events...
March 8, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28270967/normalization-of-compression-induced-hemodynamics-in-patients-responding-to-neoadjuvant-chemotherapy-monitored-by-dynamic-tomographic-optical-breast-imaging-dtobi
#14
Amir Y Sajjadi, Steven J Isakoff, Bin Deng, Bhawana Singh, Christy M Wanyo, Qianqian Fang, Michelle C Specht, Lidia Schapira, Beverly Moy, Aditya Bardia, David A Boas, Stefan A Carp
We characterize novel breast cancer imaging biomarkers for monitoring neoadjuvant chemotherapy (NACT) and predicting outcome. Specifically, we recruited 30 patients for a pilot study in which NACT patients were imaged using dynamic tomographic optical breast imaging (DTOBI) to quantify the hemodynamic changes due to partial mammographic compression. DTOBI scans were obtained pre-treatment (referred to as day 0), as well as 7 and 30 days into therapy on female patients undergoing NACT. We present data for the 13 patients who participated in both day 0 and 7 measurements and had evaluable data, of which 7 also returned for day 30 measurements...
February 1, 2017: Biomedical Optics Express
https://www.readbyqxmd.com/read/28270181/weekly-taxane-anthracycline-combination-regimen-versus-tri-weekly-anthracycline-based-regimen-for-the-treatment-of-locally-advanced-breast-cancer-a-randomized-controlled-trial
#15
Qiu-Wen Tan, Ting Luo, Hong Zheng, Ting-Lun Tian, Ping He, Jie Chen, He-Lin Zeng, Qing Lv
BACKGROUND: Extensive studies have confirmed the efficacy of taxanes in combination with anthracycline-based chemotherapy on breast cancer. However, few studies have assessed the efficacy of weekly taxane-anthracycline regimens on locally advanced breast cancer. This study was to compare the efficacy and safety of a weekly taxane-anthracycline regimen with those of tri-weekly anthracycline-based regimen in patients with locally advanced breast cancer. METHODS: Patients with locally advanced breast cancer were randomized to receive 4-6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracil-epirubicin-cyclophosphamide (FEC) regimen or weekly paclitaxel-epirubicin (PE) regimen...
March 7, 2017: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/28270088/neoadjuvant-therapy-for-patients-with-triple-negative-breast-cancer-tnbc
#16
A Rody, Liedtke Cornelia
BACKGROUND: Patients with triple negative breast cancer (TNBC) are characterized by an unfavorable prognosis particularly when not responding well to anthracycline-taxane chemotherapy. This is due to a more aggressive biology in some cases but most importantly to a lack of agents other than conventional chemotherapy. Hence, there is an urgent need to optimize therapy of patients with TNBC in order to improve prognosis. OBJECTIVE: The objective of this review is to present the current understanding of TNBC biology and give an insight of surrent theraoeutic concepts in the neoadjuvant treatment setting...
March 6, 2017: Reviews on Recent Clinical Trials
https://www.readbyqxmd.com/read/28256629/personalized-chemotherapy-selection-for-breast-cancer-using-gene-expression-profiles
#17
Kaixian Yu, Qing-Xiang Amy Sang, Pei-Yau Lung, Winston Tan, Ty Lively, Cedric Sheffield, Mayassa J Bou-Dargham, Jun S Liu, Jinfeng Zhang
Choosing the optimal chemotherapy regimen is still an unmet medical need for breast cancer patients. In this study, we reanalyzed data from seven independent data sets with totally 1079 breast cancer patients. The patients were treated with three different types of commonly used neoadjuvant chemotherapies: anthracycline alone, anthracycline plus paclitaxel, and anthracycline plus docetaxel. We developed random forest models with variable selection using both genetic and clinical variables to predict the response of a patient using pCR (pathological complete response) as the measure of response...
March 3, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28253723/effect-of-small-and-radical-surgical-injury-on-the-level-of-different-populations-of-circulating-tumor-cells-in-the-blood-of-breast-cancer-patients
#18
E V Kaigorodova, N A Tarabanovskaya, M N Staheeva, O E Savelieva, L A Tashireva, E V Denisov, V M Perelmuter
Circulating tumor cells (CTCs) constitute a heterogeneous population. Some tumor cells are cancer stem cells (CSCs), while others are in the process of the epithelial-mesenchymal transition (EMT); however, most CTCs are neither stem cells nor in the EMT. This prospective study of 22 patients with nonspecific-type invasive carcinoma of the breast identified different populations of CTCs by flow cytometry in the blood of patients before biopsy, after biopsy and after surgical tumor removal without neoadjuvant chemotherapy...
March 3, 2017: Neoplasma
https://www.readbyqxmd.com/read/28253722/evaluation-of-the-efficacy-of-neoadjuvant-chemotherapy-for-breast-cancer-using-diffusion-weighted-imaging-and-dynamic-contrast-enhanced-magnetic-resonance-imaging
#19
H D Xu, Y Q Zhang
This study aims to investigate the predictive values of diffusion-weighted imaging (DWI) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in evaluating the efficacy of neoadjuvant chemotherapy (NAC) for breast cancer. Between September 2011 and December 2014, a total of 174 patients with locally advanced breast cancer treated with NAC were selected for this study. Conventional CT and MRI examinations (DWI and DCE-MRI) were performed in all patients before NAC (T0), after the first course (T1) and after the whole course (T2) of NAC...
March 3, 2017: Neoplasma
https://www.readbyqxmd.com/read/28247605/-efficacy-of-adjuvant-endocrine-therapy-in-breast-cancer-patients-with-a-positive-to-negative-switch-of-hormone-receptor-status-after-neoadjuvant-chemotherapy
#20
Guangfa Xia, Juanying Zhu, Jun Yuan, Bo Cao, Jie Tang, Yiding Chen
Objective: To evaluate the efficacy of adjuvant endocrine therapy (AET) in breast cancer patients with a positive-to-negative switch of hormone receptor status after neoadjuvant chemotherapy (NAC). Methods: One hundred and six patients who presented with hormone receptor (HR)-positive breast cancer at diagnosis and turned to HR-negative after NAC during December 2000 and December 2013 in Jiaxing Maternity and Child Health Care Hospital were retrospectively identified. Kaplan-Meier analysis and log-rank test were used for univariate analyses of factors related to disease free survival (DFS) and overall survival (OS)...
May 25, 2016: Zhejiang da Xue Xue Bao. Yi Xue Ban, Journal of Zhejiang University. Medical Sciences
keyword
keyword
55508
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"